ReviewEuropean journal of nuclear medicine and molecular imaging2012
Rationale for the use of radiolabelled peptides in diagnosis and therapy.
Review in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Anti-Cancer Peptides: Status and Future Prospects.Molecules (Basel, Switzerland) · 2023Review
- Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides.Pharmaceutics · 2022Review
- Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors.Brain tumor research and treatment · 2018Review
- Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.World journal of gastrointestinal oncology · 2016Review
- 18F-Labeled Peptides: The Future Is Bright.Molecules (Basel, Switzerland) · 2014Review
- Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.Molecular imaging and biology · 2014Article
- Design and applications of bispecific heterodimers: molecular imaging and beyond.Molecular pharmaceutics · 2014Review
- Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate.Cancer biotherapy & radiopharmaceuticals · 2014Article
- Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography.Nature protocols · 2014Article
- Prospective of ⁶⁸Ga-radiopharmaceutical development.Theranostics · 2013Review
- Radiolabelled peptides in diagnosis and therapy: an introduction.European journal of nuclear medicine and molecular imaging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear medicine techniques are becoming more important in imaging oncological and infectious diseases. For metabolic imaging of these diseases, antibody and peptide imaging are currently used. In recent years peptide imaging has become important, therefore the rationale for the use of peptide imaging is described in this article. Criteria for a successful peptide tracer are a high target specificity, a high binding affinity, a long metabolic stability and a high target-to-background ratio. Tracer internalization is also beneficial. For oncological imaging, many tracers are available, most originating from regulatory peptides, but penetrating peptides are also being developed. Peptides for imaging inflammatory and infectious diseases include regulatory peptides, antimicrobial peptides and others. In conclusion, for the imaging of oncological, imflammatory and infectious diseases, many promising peptides are being developed. The ideal peptide probe is characterized by rapid and specific target localization and binding with a high tumour-to-background ratio.
Indexed as
Identifiers
22388630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.